MLTX MoonLake Immunotherapeutics Forecast, Technical & Fundamental Analysis
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases... Show more
MLTX is expected to report earnings to fall 5.00% to -93 cents per share on August 12
Q2'26
Est.
$-0.93
Q1'26
Missed
by $0.09
Q4'25
Beat
by $0.06
Q3'25
Missed
by $0.22
Q2'25
Missed
by $0.15
The last earnings report on May 11 showed earnings per share of -98 cents, missing the estimate of -88 cents. With 393.52K shares outstanding, the current market capitalization sits at 1.59B.
A.I.dvisor indicates that over the last year, MLTX has been closely correlated with KALA. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if MLTX jumps, then KALA could also see price increases.
MLTX sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for MLTX moved above the 200-day moving average on June 25, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
MLTX moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MLTX advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 185 cases where MLTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for MLTX moved out of overbought territory on June 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where MLTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MLTX as a result. In of 117 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MLTX turned negative on July 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MLTX broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.254) is normal, around the industry mean (20.985). P/E Ratio (0.000) is within average values for comparable stocks, (37.521). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). MLTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (422.678).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MLTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
